A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction

AIMS: The TOPCAT trial showed no benefit for spironolactone in heart failure patients with preserved ejection fraction (HFpEF). Post‐hoc, spironolactone helped participants from the Americas, but not Eastern Europe. Determining which patients with HFpEF could respond like TOPCAT's responders sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Belkin, Mark N., Blair, John E., Shah, Sanjiv J., Alenghat, Francis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497352/
https://www.ncbi.nlm.nih.gov/pubmed/34369088
http://dx.doi.org/10.1002/ehf2.13523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497352/
https://www.ncbi.nlm.nih.gov/pubmed/34369088
http://dx.doi.org/10.1002/ehf2.13523

Ejemplares similares